{"version":"1.0","provider_name":"Vigilant Biosciences\u00ae\u00ae sviluppa metodi avanzati e accurati per facilitare il rilevamento precoce del tumore orale identificando diversi biomarcatori unici che si sono dimostrati associati al tumore orale. Scopra come questa tecnologia salvavita pu\u00f2 fare la differenza per i suoi pazienti.","provider_url":"https:\/\/vigilantbiosciences.com\/it","author_name":"Wendy Vrijenhoek","author_url":"https:\/\/vigilantbiosciences.com\/it\/author\/wendy-vrijenhoek\/","title":"Miles Massidda - Vigilant Biosciences\u00ae","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"odKZ1eSGoR\"><a href=\"https:\/\/vigilantbiosciences.com\/it\/dipl-team-member\/miglia-massidda\/\">Miles Massidda<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/vigilantbiosciences.com\/it\/dipl-team-member\/miglia-massidda\/embed\/#?secret=odKZ1eSGoR\" width=\"600\" height=\"338\" title=\"&#8220;Miles Massidda&#8221; &#8212; Vigilant Biosciences\u00ae\" data-secret=\"odKZ1eSGoR\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/vigilantbiosciences.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>","thumbnail_url":"https:\/\/vigilantbiosciences.com\/wp-content\/uploads\/Miles-Massidda_720x720.jpg","thumbnail_width":720,"thumbnail_height":720,"description":"Miles Massidda serves as Manager of Research &amp; Development at Vigilant Biosciences\u00ae, where he leads the expansion of the company&#8217;s diagnostic platform, spearheading the development of four novel lateral flow immunoassays for the detection of oral cancer, HPV, candidiasis, and aspergillosis. His work supports Vigilant&#8217;s mission of bringing earlier, more accessible disease detection to patients [&hellip;]"}